^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
VOTRIENT is a kinase inhibitor indicated for the treatment of patients with:...advanced renal cell carcinoma (RCC).
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...non-clear cell RCC patients found treatment with pazopanib to be effective and safe...the NCCN Kidney Cancer Panel has included these therapies as a therapy option for patients with relapsed or medically unresectable stage IV disease with non-clear cell histology (category 2A)...